SOME ERECTILE dysfunction (ED) researchers and pharmaceutical manufacturers may be suffering a bit of sildenafil envy these days, but recent findings give hope to those wishing to slow the Viagra prescription juggernaut.
Researchers at last month's 93rd Annual Meeting of the American Urology Association (AUA), held in San Diego, Calif, presented studies promoting alternatives to Viagra (sildenafil citrate), the cGMP-specific type 5 phosphodiesterase (PDE5) inhibitor manufactured by New York, NY–based Pfizer Inc.
Mitka M. Viagra Leads as Rivals Are Moving Up. JAMA. 1998;280(2):119–120. doi:10.1001/jama.280.2.119
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: